Ferring has announced the opening of the first clinical trial sites for 2 studies within the ABLE clinical trial program as well as the launch of the phase 1/2 LUNAR trial. “The combination of ...

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies ...

IPP placement is associated with improved penile length and width ...

Would you please start by giving a brief overview of BCG-unresponsive NMIBC? Nonmuscle Invasive Bladder Cancer Prior to recent therapeutic innovations in the bladder space what challenges or unmet ...

IPP placement is associated with improved penile length and width ...

"The interplay between the microbiome and bladder cancer is very complex," says Ilaha Isali, MD, MSc. Isali: The interplay between the microbiome and bladder cancer is very complex. There is still ...

Please review the standard treatment options (intravesical chemotherapy, PD-L1 inhibitors, other immunotherapeutic options) currently available for patients with BCG-unresponsive NMIBC.

Bayer seeks approval in China for darolutamide plus ADT for mHSPC, marking a potential third indication. The ARANOTE trial showed darolutamide plus ADT significantly improved rPFS and OS compared to ...

"This idea that physicians and medical teams always feel that they need to be available at all hours of the day really starts to stress people." says Chad W. M. Ritenour, MD, FACS. In this video, Chad ...

According to iota Biosciences, the device is “designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by ...

Sunobinop resulted in a reduction in urinary urgency, urinary frequency, and incontinence episodes over the treatment period compared with placebo.